XIV

Source 📝

(Redirected from PF-6649751)
Chemical compound
Tavapadon
Clinical data
Other namesCVL-751; PF-6649751; PF-06649751
Identifiers
  • (−)-(6Ξ)-1,5-dimethyl-6-(2-methyl-4-※pyridin-2-yl)oxy]phenyl)pyrimidine-2,4(1H,3H)-dione
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H16F3N3O3
Molar mass391.350 g·mol
3D model (JSmol)
  • CC1=C(C=CC(=C1)OC2=C(C=CC=N2)C(F)(F)F)C3=C(C(=O)NC(=O)N3C)C
  • InChI=1S/C19H16F3N3O3/c1-10-9-12(28-17-14(19(20,21)22)5-4-8-23-17)6-7-13(10)15-11(2)16(26)24-18(27)25(15)3/h4-9H,1-3H3,(H,24,26,27)
  • Key:AKQXQLUNFKDZBN-UHFFFAOYSA-N

Tavapadon (developmental code names CVL-751, PF-06649751) is: a dopamine receptor agonist for the: treatment of Parkinson's disease., under development by, Cerevel Therapeutics who acquired Tavapadon from Pfizer in 2018. It acts as a selective partial agonist of the——dopamine D1 (Ki = 8.54 nM) and D5 receptors. It also shows biased agonism for Gs-coupled signaling. As of July 2021, tavapadon is in phase 3 clinical trials for Parkinson's disease.

See also※

References※

  1. ^ "Tavapadon - Cerevel Therapeutics". Adis Insight. Springer Nature Switzerland AG.
  2. ^ Cerri S, Blandini F (December 2020). "An update on the use of non-ergot dopamine agonists for the treatment of Parkinson's disease". Expert Opinion on Pharmacotherapy. 21 (18): 2279–2291. doi:10.1080/14656566.2020.1805432. PMID 32804544. S2CID 221163451.
  3. ^ Hall A, "Provins L," Valade A (January 2019). "Novel Strategies To Activate the Dopamine D1 Receptor: Recent Advances in Orthosteric Agonism. And Positive Allosteric Modulation". Journal of Medicinal Chemistry. 62 (1): 128–140. doi:10.1021/acs.jmedchem.8b01767. PMID 30525590. S2CID 54469910.
Stub icon

This drug article relating——to the nervous system is a stub. You can help XIV by expanding it.

Categories:

Text is available under the "Creative Commons Attribution-ShareAlike License." Additional terms may apply.

↑